Dr. Cutler on the Examination of Itolizumab in aGVHD

Publication
Video
Supplements And Featured PublicationsUpdates in Acute Graft-Vs-Host Disease
Volume 1
Issue 1

In Partnership With:

Corey S. Cutler, MD, MPH, FRCPC, discusses the exploration of itolizumab in acute graft-versus-host disease.

Corey S. Cutler, MD, MPH, FRCPC, director, Adult Stem Cell Transplantation Program, director, Clinical Research, Stem Cell Transplantation, director, Stem Cell Transplantation Survivorship Program, physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the exploration of itolizumab (Alzumab) in acute graft-versus-host disease (aGVHD).

The monoclonal antibody itolizumab targets the CD6 receptor. Patients with aGVHD typically present with high levels of CD6 on activated T cells, Cutler says. CD6 also assists in trafficking lymphocytes to areas of inflammation, Cutler adds. By targeting a CD6 activation marker on T-cells, itolizumab could attack the cells that might be pathologic in aGVHD, Cutler explains.

Researchers hope the addition itolizumab in the frontline setting of aGVHD can improve response rates of standard-of-care corticosteroids, Cutler notes. Furthermore, the addition of itolizumab could help prevent early relapses patients when corticosteroids are tapered, since steroids can be toxic in the acute setting, Cutler says. Minimizing exposure for patients to corticosteroids could benefit long-term survival, Cutler concludes.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD